BTRC Conversations: The Fight Against Brain Tumours
Dr Christian Smith
1 episodes
9 months ago
The lab of Peter Dirks investigates how medulloblastoma stem cells transition from a dormant state to an active, proliferative state, a process regulated by the transcription factor Olig2. The scientists found that inactivating Olig2 prevents stem cell activation, thereby blocking tumour growth. Targeting Olig2 with a small molecule inhibitor, CT-179, significantly slowed early tumour formation and regrowth after therapy in a mouse model. Further analysis revealed the drug effectively limits ...
All content for BTRC Conversations: The Fight Against Brain Tumours is the property of Dr Christian Smith and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The lab of Peter Dirks investigates how medulloblastoma stem cells transition from a dormant state to an active, proliferative state, a process regulated by the transcription factor Olig2. The scientists found that inactivating Olig2 prevents stem cell activation, thereby blocking tumour growth. Targeting Olig2 with a small molecule inhibitor, CT-179, significantly slowed early tumour formation and regrowth after therapy in a mouse model. Further analysis revealed the drug effectively limits ...
The lab of Peter Dirks investigates how medulloblastoma stem cells transition from a dormant state to an active, proliferative state, a process regulated by the transcription factor Olig2. The scientists found that inactivating Olig2 prevents stem cell activation, thereby blocking tumour growth. Targeting Olig2 with a small molecule inhibitor, CT-179, significantly slowed early tumour formation and regrowth after therapy in a mouse model. Further analysis revealed the drug effectively limits ...
BTRC Conversations: The Fight Against Brain Tumours
The lab of Peter Dirks investigates how medulloblastoma stem cells transition from a dormant state to an active, proliferative state, a process regulated by the transcription factor Olig2. The scientists found that inactivating Olig2 prevents stem cell activation, thereby blocking tumour growth. Targeting Olig2 with a small molecule inhibitor, CT-179, significantly slowed early tumour formation and regrowth after therapy in a mouse model. Further analysis revealed the drug effectively limits ...
